{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T02:36:31Z","timestamp":1779935791669,"version":"3.53.1"},"publisher-location":"Cham","reference-count":148,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783031153044","type":"print"},{"value":"9783031153051","type":"electronic"}],"license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"DOI":"10.1007\/82_2021_245","type":"book-chapter","created":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T18:02:56Z","timestamp":1643652176000},"page":"223-246","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Immune Responses to Varicella-Zoster Virus Vaccines"],"prefix":"10.1007","author":[{"given":"Myron J.","family":"Levin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6920-0623","authenticated-orcid":false,"given":"Adriana","family":"Weinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,1]]},"reference":[{"issue":"19","key":"245_CR1","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1056\/NEJMoa066092","volume":"357","author":"IJ Amanna","year":"2007","unstructured":"Amanna IJ, Carlson NE, Slifka MK (2007) Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 357(19):1903\u20131915","journal-title":"N Engl J Med"},{"key":"245_CR2","doi-asserted-by":"crossref","unstructured":"Ansari R et al (2021) Primary and Acquired Immunodeficiencies Associated with Severe Varicella-Zoster Infections. Clin Infect Dis 73:e2705\u2013e2712","DOI":"10.1093\/cid\/ciaa1274"},{"issue":"4 Pt 2","key":"245_CR3","first-page":"748","volume":"78","author":"AM Arbeter","year":"1986","unstructured":"Arbeter AM, Starr SE, Plotkin SA (1986) Varicella vaccine studies in healthy children and adults. Pediatrics 78(4 Pt 2):748\u2013756","journal-title":"Pediatrics"},{"issue":"4","key":"245_CR4","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1172\/JCI109739","volume":"65","author":"AM Arvin","year":"1980","unstructured":"Arvin AM et al (1980) Cellular and humoral immunity in the pathogenesis of recurrent herpes viral infections in patients with lymphoma. J Clin Invest 65(4):869\u2013878","journal-title":"J Clin Invest"},{"issue":"2","key":"245_CR5","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1093\/infdis\/148.2.200","volume":"148","author":"AM Arvin","year":"1983","unstructured":"Arvin AM, Koropchak CM, Wittek AE (1983) Immunologic evidence of reinfection with varicella-zoster virus. J Infect Dis 148(2):200\u2013205","journal-title":"J Infect Dis"},{"issue":"44","key":"245_CR6","doi-asserted-by":"publisher","first-page":"6776","DOI":"10.1016\/j.vaccine.2019.09.031","volume":"37","author":"H Asada","year":"2019","unstructured":"Asada H (2019) VZV-specific cell-mediated immunity, but not humoral immunity, correlates inversely with the incidence of herpes zoster and the severity of skin symptoms and zoster-associated pain: the SHEZ study. Vaccine 37(44):6776\u20136781","journal-title":"Vaccine"},{"issue":"6","key":"245_CR7","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1542\/peds.80.6.933","volume":"80","author":"Y Asano","year":"1987","unstructured":"Asano Y et al (1987) Immunoglobulin subclass antibodies to varicella-zoster virus. Pediatrics 80(6):933\u2013936","journal-title":"Pediatrics"},{"issue":"4 Pt 1","key":"245_CR8","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1542\/peds.94.4.524","volume":"94","author":"Y Asano","year":"1994","unstructured":"Asano Y et al (1994) Experience and reason: twenty-year follow-up of protective immunity of the Oka strain live varicella vaccine. Pediatrics 94(4 Pt 1):524\u2013526","journal-title":"Pediatrics"},{"issue":"6","key":"245_CR9","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/S0022-3476(82)80505-2","volume":"100","author":"K Baba","year":"1982","unstructured":"Baba K et al (1982) Immunologic and epidemiologic aspects of varicella infection acquired during infancy and early childhood. J Pediatr 100(6):881\u2013885","journal-title":"J Pediatr"},{"issue":"5","key":"245_CR10","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/S0022-3476(84)80288-7","volume":"105","author":"K Baba","year":"1984","unstructured":"Baba K et al (1984) Seroepidemiologic behavior of varicella zoster virus infection in a semiclosed community after introduction of VZV vaccine. J Pediatr 105(5):712\u2013716","journal-title":"J Pediatr"},{"issue":"8","key":"245_CR11","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/infdis\/jiu606","volume":"211","author":"EM Berkowitz","year":"2015","unstructured":"Berkowitz EM et al (2015) Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1\/2a randomized, placebo-controlled study. J Infect Dis 211(8):1279\u20131287","journal-title":"J Infect Dis"},{"issue":"6","key":"245_CR12","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1542\/peds.92.6.833","volume":"92","author":"HH Bernstein","year":"1993","unstructured":"Bernstein HH et al (1993) Clinical survey of natural varicella compared with breakthrough varicella after immunization with live attenuated Oka\/Merck varicella vaccine. Pediatrics 92(6):833\u2013837","journal-title":"Pediatrics"},{"issue":"5","key":"245_CR13","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1084\/jem.20181365","volume":"216","author":"LK Beura","year":"2019","unstructured":"Beura LK et al (2019) CD4+ resident memory T cells dominate immunosurveillance and orchestrate local recall responses. J Exp Med 216(5):1214\u20131229","journal-title":"J Exp Med"},{"issue":"1","key":"245_CR14","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1186\/s12879-021-06180-x","volume":"21","author":"FP Bianchi","year":"2021","unstructured":"Bianchi FP et al (2021) Long-term persistence of antibodies against varicella in fully immunized healthcare workers: an Italian retrospective cohort study. BMC Infect Dis 21(1):475","journal-title":"BMC Infect Dis"},{"issue":"Suppl 2","key":"245_CR15","doi-asserted-by":"publisher","first-page":"S139","DOI":"10.1086\/522124","volume":"197","author":"S Black","year":"2008","unstructured":"Black S et al (2008) Lack of association between age at varicella vaccination and risk of breakthrough varicella, within the Northern California Kaiser Permanente Medical Care Program. J Infect Dis 197(Suppl 2):S139\u2013S142","journal-title":"J Infect Dis"},{"key":"245_CR16","doi-asserted-by":"crossref","unstructured":"Boeckh MJ et al (2020) Immunogenicity of Inactivated Varicella Zoster Vaccine in Autologous Hematopoietic Stem Cell Transplant Recipients and Patients With Solid or Hematologic Cancer. Open Forum Infect Dis 7(7):ofaa172","DOI":"10.1093\/ofid\/ofaa172"},{"issue":"2","key":"245_CR17","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1093\/infdis\/146.2.260","volume":"146","author":"S Bogger-Goren","year":"1982","unstructured":"Bogger-Goren S et al (1982) Antibody response to varicella-zoster virus after natural or vaccine-induced infection. J Infect Dis 146(2):260\u2013265","journal-title":"J Infect Dis"},{"key":"245_CR18","doi-asserted-by":"crossref","unstructured":"Boutry C et al (2021, in press) The adjuvanted recombinant zoster vaccine confers long-term protection against herpes zoster: interim results of an extension study of the pivotal phase 3 clinical trials ZOE-50 and ZOE-70. Clin Infect Dis","DOI":"10.1093\/ofid\/ofaa417.007"},{"issue":"12","key":"245_CR19","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.it.2004.09.013","volume":"25","author":"FR Carbone","year":"2004","unstructured":"Carbone FR, Belz GT, Heath WR (2004) Transfer of antigen between migrating and lymph node-resident DCs in peripheral T-cell tolerance and immunity. Trends Immunol 25(12):655\u2013658","journal-title":"Trends Immunol"},{"issue":"11","key":"245_CR20","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1056\/NEJMoa064040","volume":"356","author":"SS Chaves","year":"2007","unstructured":"Chaves SS et al (2007) Loss of vaccine-induced immunity to varicella over time. N Engl J Med 356(11):1121\u20131129","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"245_CR21","doi-asserted-by":"publisher","first-page":"S127","DOI":"10.1086\/522150","volume":"197","author":"SS Chaves","year":"2008","unstructured":"Chaves SS et al (2008) Varicella disease among vaccinated persons: clinical and epidemiological characteristics, 1997\u20132005. J Infect Dis 197(Suppl 2):S127\u2013S131","journal-title":"J Infect Dis"},{"issue":"15","key":"245_CR22","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1016\/j.vaccine.2014.01.019","volume":"32","author":"R Chlibek","year":"2014","unstructured":"Chlibek R et al (2014) Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study. Vaccine 32(15):1745\u20131753","journal-title":"Vaccine"},{"issue":"6","key":"245_CR23","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.vaccine.2015.09.073","volume":"34","author":"R Chlibek","year":"2016","unstructured":"Chlibek R et al (2016) Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults. Vaccine 34(6):863\u2013868","journal-title":"Vaccine"},{"issue":"1","key":"245_CR24","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12879-021-05806-4","volume":"21","author":"JY Chun","year":"2021","unstructured":"Chun JY et al (2021) Immunogenicity and safety of a live herpes zoster vaccine in hematopoietic stem cell transplant recipients. BMC Infect Dis 21(1):117","journal-title":"BMC Infect Dis"},{"issue":"11","key":"245_CR25","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1097\/INF.0b013e3181a90b16","volume":"28","author":"R Civen","year":"2009","unstructured":"Civen R et al (2009) The incidence and clinical characteristics of herpes zoster among children and adolescents after implementation of varicella vaccination. Pediatr Infect Dis J 28(11):954\u2013959","journal-title":"Pediatr Infect Dis J"},{"key":"245_CR26","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41541-017-0027-3","volume":"2","author":"M Coccia","year":"2017","unstructured":"Coccia M et al (2017) Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFN\u03b3 response promoting vaccine immunogenicity. NPJ Vaccines 2:25","journal-title":"NPJ Vaccines"},{"issue":"11","key":"245_CR27","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1080\/21645515.2020.1741312","volume":"16","author":"R Colindres","year":"2020","unstructured":"Colindres R et al (2020) Post hoc analysis of reactogenicity trends between dose 1 and dose 2 of the adjuvanted recombinant zoster vaccine in two parallel randomized trials. Hum Vaccin Immunother 16(11):2628\u20132633","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"245_CR28","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1385\/CRIAI:19:2:183","volume":"19","author":"ME Conley","year":"2000","unstructured":"Conley ME, Rohrer J, Minegishi Y (2000) X-linked agammaglobulinemia. Clin Rev Allergy Immunol 19(2):183\u2013204","journal-title":"Clin Rev Allergy Immunol"},{"issue":"11","key":"245_CR29","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1093\/infdis\/jiy095","volume":"217","author":"AL Cunningham","year":"2018","unstructured":"Cunningham AL et al (2018) Immune responses to a recombinant glycoprotein E herpes zoster vaccine in adults aged 50 years or older. J Infect Dis 217(11):1750\u20131760","journal-title":"J Infect Dis"},{"issue":"12","key":"245_CR30","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1016\/j.bbmt.2019.07.036","volume":"25","author":"D Curran","year":"2019","unstructured":"Curran D et al (2019) Recombinant zoster vaccine significantly reduces the impact on quality of life caused by herpes zoster in adult autologous hematopoietic stem cell transplant recipients: a randomized placebo-controlled trial (ZOE-HSCT). Biol Blood Marrow Transplant 25(12):2474\u20132481","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"245_CR31","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1111\/jgs.16917","volume":"69","author":"D Curran","year":"2021","unstructured":"Curran D et al (2021) Recombinant zoster vaccine is efficacious and safe in frail individuals. J Am Geriatr Soc 69(3):744\u2013752","journal-title":"J Am Geriatr Soc"},{"key":"245_CR32","doi-asserted-by":"crossref","unstructured":"Curtis JR et al (2021) The safety and immunologic effectiveness of the live varicella-zoster vaccine in patients receiving tumor necrosis factor inhibitor therapy. Ann Intern Med 174:1510\u20131518","DOI":"10.7326\/M20-6928"},{"issue":"3","key":"245_CR33","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.cell.2019.03.016","volume":"177","author":"JG Cyster","year":"2019","unstructured":"Cyster JG, Allen CDC (2019) B cell responses: cell interaction dynamics and decisions. Cell 177(3):524\u2013540","journal-title":"Cell"},{"issue":"6","key":"245_CR34","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.4049\/jimmunol.1601367","volume":"198","author":"B Davies","year":"2017","unstructured":"Davies B et al (2017) Cutting edge: tissue-resident memory T cells generated by multiple immunizations or localized deposition provide enhanced immunity. J Immunol 198(6):2233\u20132237","journal-title":"J Immunol"},{"key":"245_CR35","doi-asserted-by":"publisher","first-page":"13324","DOI":"10.1038\/ncomms13324","volume":"7","author":"MH den Brok","year":"2016","unstructured":"den Brok MH et al (2016) Saponin-based adjuvants induce cross-presentation in dendritic cells by intracellular lipid body formation. Nat Commun 7:13324","journal-title":"Nat Commun"},{"issue":"3","key":"245_CR36","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1542\/peds.88.3.604","volume":"88","author":"PH Dennehy","year":"1991","unstructured":"Dennehy PH et al (1991) Immunogenicity of subcutaneous versus intramuscular Oka\/Merck varicella vaccination in healthy children. Pediatrics 88(3):604\u2013607","journal-title":"Pediatrics"},{"issue":"6","key":"245_CR37","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1093\/infdis\/158.6.1245","volume":"158","author":"PS Diaz","year":"1988","unstructured":"Diaz PS et al (1988) Immunity to whole varicella-zoster virus antigen and glycoproteins I and p170: relation to the immunizing regimen of live attenuated varicella vaccine. J Infect Dis 158(6):1245\u20131252","journal-title":"J Infect Dis"},{"issue":"47\u201348","key":"245_CR38","doi-asserted-by":"publisher","first-page":"6875","DOI":"10.1016\/j.vaccine.2006.06.030","volume":"24","author":"C Diaz","year":"2006","unstructured":"Diaz C et al (2006) Safety, tolerability, and immunogenicity of a two-dose regimen of high-titer varicella vaccine in subjects > or =13 years of age. Vaccine 24(47\u201348):6875\u20136885","journal-title":"Vaccine"},{"issue":"4","key":"245_CR39","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.4049\/jimmunol.1400948","volume":"193","author":"AM Didierlaurent","year":"2014","unstructured":"Didierlaurent AM et al (2014) Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells. J Immunol 193(4):1920\u20131930","journal-title":"J Immunol"},{"issue":"7","key":"245_CR40","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1093\/cid\/cix484","volume":"65","author":"M Eberhardson","year":"2017","unstructured":"Eberhardson M et al (2017) Safety and immunogenicity of inactivated varicella-zoster virus vaccine in adults with autoimmune disease: a phase 2, randomized, double-blind placebo-controlled clinical trial. Clin Infect Dis 65(7):1174\u20131182","journal-title":"Clin Infect Dis"},{"key":"245_CR41","doi-asserted-by":"crossref","unstructured":"Eberhardt CS et al (2020) Persistence of Varicella-Zoster virus-specific plasma cells in adult human bone marrow following childhood vaccination. J Virol 94(13)","DOI":"10.1128\/JVI.02127-19"},{"issue":"3","key":"245_CR42","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1542\/peds.56.3.388","volume":"56","author":"S Feldman","year":"1975","unstructured":"Feldman S, Hughes WT, Daniel CB (1975) Varicella in children with cancer: seventy-seven cases. Pediatrics 56(3):388\u2013397","journal-title":"Pediatrics"},{"issue":"4","key":"245_CR43","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1586\/erv.11.29","volume":"10","author":"N Garcon","year":"2011","unstructured":"Garcon N, Van Mechelen M (2011) Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems. Expert Rev Vaccines 10(4):471\u2013486","journal-title":"Expert Rev Vaccines"},{"issue":"1","key":"245_CR44","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1093\/infdis\/158.1.132","volume":"158","author":"AA Gershon","year":"1988","unstructured":"Gershon AA et al (1988) Immunization of healthy adults with live attenuated varicella vaccine. J Infect Dis 158(1):132\u2013137","journal-title":"J Infect Dis"},{"issue":"8","key":"245_CR45","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1093\/infdis\/jiy660","volume":"219","author":"AA Gershon","year":"2019","unstructured":"Gershon AA et al (2019) High constitutive interleukin 10 level interferes with the immune response to varicella-zoster virus in elderly recipients of live attenuated zoster vaccine. J Infect Dis 219(8):1338\u20131346","journal-title":"J Infect Dis"},{"issue":"10","key":"245_CR46","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1093\/infdis\/jiu279","volume":"210","author":"PB Gilbert","year":"2014","unstructured":"Gilbert PB et al (2014) Fold rise in antibody titers by measured by glycoprotein-based enzyme-linked immunosorbent assay is an excellent correlate of protection for a herpes zoster vaccine, demonstrated via the vaccine efficacy curve. J Infect Dis 210(10):1573\u20131581","journal-title":"J Infect Dis"},{"issue":"1","key":"245_CR47","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1542\/peds.18.1.109","volume":"18","author":"RA Good","year":"1956","unstructured":"Good RA, Zak SJ (1956) Disturbances in gamma globulin synthesis as experiments of nature. Pediatrics 18(1):109\u2013149","journal-title":"Pediatrics"},{"issue":"17","key":"245_CR48","doi-asserted-by":"publisher","first-page":"8861","DOI":"10.1128\/JVI.01020-10","volume":"84","author":"K Gowrishankar","year":"2010","unstructured":"Gowrishankar K et al (2010) Characterization of the host immune response in human Ganglia after herpes zoster. J Virol 84(17):8861\u20138870","journal-title":"J Virol"},{"issue":"Suppl 2","key":"245_CR49","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1086\/522156","volume":"197","author":"D Guris","year":"2008","unstructured":"Guris D et al (2008) Changing varicella epidemiology in active surveillance sites\u2013United States, 1995\u20132005. J Infect Dis 197(Suppl 2):S71\u2013S75","journal-title":"J Infect Dis"},{"key":"245_CR50","doi-asserted-by":"crossref","unstructured":"Haberthur K et al (2011) CD4 T cell immunity is critical for the control of simian varicella virus infection in a nonhuman primate model of VZV infection. PLoS Pathog 7(11):e1002367","DOI":"10.1371\/journal.ppat.1002367"},{"key":"245_CR51","doi-asserted-by":"crossref","unstructured":"Harada K et al (2017) Zoster vaccine-associated primary varicella infection in an immunocompetent host. BMJ Case Rep, bcr2017221166","DOI":"10.1136\/bcr-2017-221166"},{"issue":"2","key":"245_CR52","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1093\/cid\/ciy954","volume":"69","author":"R Harpaz","year":"2019","unstructured":"Harpaz R, Leung JW (2019) The epidemiology of herpes zoster in the United States during the era of varicella and herpes zoster vaccines: changing patterns among children. Clin Infect Dis 69(2):345\u2013347","journal-title":"Clin Infect Dis"},{"key":"245_CR53","doi-asserted-by":"crossref","unstructured":"Hastie A et al (2020) Immunogenicity of the adjuvanted recombinant zoster vaccine: persistence and anamnestic response to additional doses administered 10 years after primary vaccination. J Infect Dis","DOI":"10.1093\/infdis\/jiaa300"},{"issue":"1","key":"245_CR54","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1056\/NEJMoa013441","volume":"347","author":"A Hata","year":"2002","unstructured":"Hata A et al (2002) Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med 347(1):26\u201334","journal-title":"N Engl J Med"},{"issue":"1","key":"245_CR55","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1002\/(SICI)1096-9071(199709)53:1<63::AID-JMV11>3.0.CO;2-Y","volume":"53","author":"M Haumont","year":"1997","unstructured":"Haumont M et al (1997) Neutralizing antibody responses induced by varicella-zoster virus gE and gB glycoproteins following infection, reactivation or immunization. J Med Virol 53(1):63\u201368","journal-title":"J Med Virol"},{"key":"245_CR56","doi-asserted-by":"crossref","unstructured":"Hirosue S et al (2015) Modes of Antigen Presentation by Lymph Node Stromal Cells and Their Immunological Implications. Front Immunol 6(446).","DOI":"10.3389\/fimmu.2015.00446"},{"issue":"1","key":"245_CR57","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/j.1442-200X.1991.tb01518.x","volume":"33","author":"T Ihara","year":"1991","unstructured":"Ihara T et al (1991) Antibody response determined with antibody-dependent cell-mediated cytotoxicity (ADCC), neutralizing antibody, and varicella skin test in children with natural varicella and after varicella immunization. Acta Paediatr Jpn 33(1):43\u201349","journal-title":"Acta Paediatr Jpn"},{"issue":"6","key":"245_CR58","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1093\/cid\/ciw854","volume":"64","author":"HS Izurieta","year":"2017","unstructured":"Izurieta HS et al (2017) Effectiveness and duration of protection provided by the live-attenuated herpes zoster vaccine in the Medicare population ages 65 years and older. Clin Infect Dis 64(6):785\u2013793","journal-title":"Clin Infect Dis"},{"issue":"36","key":"245_CR59","doi-asserted-by":"publisher","first-page":"5422","DOI":"10.1016\/j.vaccine.2019.07.004","volume":"37","author":"NP Klein","year":"2019","unstructured":"Klein NP et al (2019) Long-term effectiveness of zoster vaccine live for postherpetic neuralgia prevention. Vaccine 37(36):5422\u20135427","journal-title":"Vaccine"},{"issue":"1","key":"245_CR60","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1097\/01.inf.0000195626.35239.58","volume":"25","author":"M Knuf","year":"2006","unstructured":"Knuf M et al (2006) Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children. Pediatr Infect Dis J 25(1):12\u201318","journal-title":"Pediatr Infect Dis J"},{"issue":"4","key":"245_CR61","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3899\/jrheum.170936","volume":"45","author":"JH Koh","year":"2018","unstructured":"Koh JH et al (2018) Safety, and humoral and cell-mediated immune responses to herpes zoster vaccine in patients with rheumatoid arthritis. J Rheumatol 45(4):465\u2013469","journal-title":"J Rheumatol"},{"issue":"4","key":"245_CR62","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/S0022-3476(95)70106-0","volume":"127","author":"PR Krause","year":"1995","unstructured":"Krause PR, Klinman DM (1995) Efficacy, immunogenicity, safety, and use of live attenuated chickenpox vaccine. J Pediatr 127(4):518\u2013525","journal-title":"J Pediatr"},{"issue":"11","key":"245_CR63","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/0264-410X(95)00046-4","volume":"13","author":"BJ Kuter","year":"1995","unstructured":"Kuter BJ et al (1995) Safety, tolerability, and immunogenicity of two regimens of Oka\/Merck varicella vaccine (Varivax) in healthy adolescents and adults Oka\/merck Varicella Vaccine Study Group. Vaccine 13(11):967\u2013972","journal-title":"Vaccine"},{"issue":"7","key":"245_CR64","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1093\/infdis\/jiv164","volume":"212","author":"KJ Laing","year":"2015","unstructured":"Laing KJ et al (2015) Zoster vaccination increases the breadth of CD4+ T cells responsive to varicella zoster virus. J Infect Dis 212(7):1022\u20131031","journal-title":"J Infect Dis"},{"issue":"1","key":"245_CR65","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.vaccine.2017.11.019","volume":"36","author":"H Lal","year":"2018","unstructured":"Lal H et al (2018) Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: results of a phase III, randomized, open-label, multicenter study. Vaccine 36(1):148\u2013154","journal-title":"Vaccine"},{"issue":"12","key":"245_CR66","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1093\/infdis\/jiw462","volume":"214","author":"A Lelic","year":"2016","unstructured":"Lelic A et al (2016) Immunogenicity of varicella vaccine and immunologic predictors of response in a cohort of elderly nursing home residents. J Infect Dis 214(12):1905\u20131910","journal-title":"J Infect Dis"},{"issue":"8","key":"245_CR67","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1093\/infdis\/jis497","volume":"206","author":"I Leroux-Roels","year":"2012","unstructured":"Leroux-Roels I et al (2012) A phase 1\/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults. J Infect Dis 206(8):1280\u20131290","journal-title":"J Infect Dis"},{"key":"245_CR68","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.clim.2016.05.007","volume":"169","author":"G Leroux-Roels","year":"2016","unstructured":"Leroux-Roels G et al (2016) Impact of adjuvants on CD4(+) T cell and B cell responses to a protein antigen vaccine: results from a phase II, randomized, multicenter trial. Clin Immunol 169:16\u201327","journal-title":"Clin Immunol"},{"issue":"3","key":"245_CR70","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1080\/21645515.2015.1008880","volume":"11","author":"J Leung","year":"2015","unstructured":"Leung J, Bialek SR, Marin M (2015) Trends in varicella mortality in the United States: data from vital statistics and the national surveillance system. Hum Vaccin Immunother 11(3):662\u2013668","journal-title":"Hum Vaccin Immunother"},{"issue":"4","key":"245_CR69","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1093\/jpids\/piv044","volume":"5","author":"J Leung","year":"2016","unstructured":"Leung J, Harpaz R (2016) Impact of the maturing varicella vaccination program on Varicella and related outcomes in the United States: 1994\u20132012. J Pediatric Infect Dis Soc 5(4):395\u2013402","journal-title":"J Pediatric Infect Dis Soc"},{"key":"245_CR71","first-page":"151","volume":"17","author":"MJ Levin","year":"2001","unstructured":"Levin MJ (2001) Use of varicella vaccines to prevent herpes zoster in older individuals. Arch Virol Suppl 17:151\u2013160","journal-title":"Arch Virol Suppl"},{"issue":"4","key":"245_CR72","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.jcv.2014.09.012","volume":"61","author":"MJ Levin","year":"2014","unstructured":"Levin MJ (2014) Varicella-zoster virus and virus DNA in the blood and oropharynx of people with latent or active varicella-zoster virus infections. J Clin Virol 61(4):487\u2013495","journal-title":"J Clin Virol"},{"key":"245_CR80","doi-asserted-by":"crossref","unstructured":"Levin MJ (2017) Zoster vaccine. In: Plotkin S, W Orenstein, P Offitt, KM Edwards (eds) Vaccines, 7th edn. Elsevier, Philadelphia, pp 1268\u20131281","DOI":"10.1016\/B978-0-323-35761-6.00065-1"},{"issue":"4","key":"245_CR73","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1080\/21645515.2018.1560918","volume":"15","author":"MJ Levin","year":"2019","unstructured":"Levin MJ, Weinberg A (2019) Immune responses to zoster vaccines. Hum Vaccin Immunother 15(4):772\u2013777","journal-title":"Hum Vaccin Immunother"},{"issue":"12","key":"245_CR74","doi-asserted-by":"publisher","first-page":"6979","DOI":"10.1128\/JVI.77.12.6979-6987.2003","volume":"77","author":"MJ Levin","year":"2003","unstructured":"Levin MJ et al (2003a) Varicella-zoster virus DNA in cells isolated from human trigeminal ganglia. J Virol 77(12):6979\u20136987","journal-title":"J Virol"},{"issue":"7","key":"245_CR75","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1086\/378502","volume":"188","author":"MJ Levin","year":"2003","unstructured":"Levin MJ et al (2003b) Development of resistance to acyclovir during chronic infection with the Oka vaccine strain of varicella-zoster virus, in an immunosuppressed child. J Infect Dis 188(7):954\u2013959","journal-title":"J Infect Dis"},{"issue":"6","key":"245_CR76","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1086\/528696","volume":"197","author":"MJ Levin","year":"2008","unstructured":"Levin MJ et al (2008) Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis 197(6):825\u2013835","journal-title":"J Infect Dis"},{"issue":"1","key":"245_CR77","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/infdis\/jiv480","volume":"213","author":"MJ Levin","year":"2015","unstructured":"Levin MJ et al (2015) Cellular and humoral responses to a second dose of herpes zoster vaccine administered 10 years after the first dose among older adults. J Infect Dis 213(1):14\u201322","journal-title":"J Infect Dis"},{"issue":"10","key":"245_CR78","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1172\/JCI121484","volume":"128","author":"MJ Levin","year":"2018","unstructured":"Levin MJ et al (2018) Th1 memory differentiates recombinant from live herpes zoster vaccines. J Clin Invest 128(10):4429\u20134440","journal-title":"J Clin Invest"},{"key":"245_CR79","doi-asserted-by":"crossref","unstructured":"Levin MJ et al (2019) Varicella zoster immune globulin (VARIZIG) administration up to 10 days after varicella exposure in pregnant women, immunocompromised participants, and infants: Varicella outcomes and safety results from a large, open-label, expanded-access program. PLoS One 14(7):e0217749","DOI":"10.1371\/journal.pone.0217749"},{"key":"245_CR82","doi-asserted-by":"crossref","unstructured":"Levin J, Cai G, Lee K, Rouphael N, Mehta A, Canniff J, Mulligan M, Weinberg A (2018) Varicella-zoster virus DNA in blood after administration of herpes zoster vaccine J Infect Dis","DOI":"10.1093\/infdis\/jix653"},{"key":"245_CR81","unstructured":"Levin M, Schmader KS, Oxman MN (2019) Varicella and herpes zoster In: Kang S, Amagai M, Bruckner AL, Enk AH, Margolis DJ, McMichael AJ, Orringer JS (eds) Fitzpatrick\u2019s dermatology. McGraw-Hill Education, New York, NY, pp 3035\u20133064"},{"issue":"4","key":"245_CR83","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1097\/00006454-200204000-00014","volume":"21","author":"S Li","year":"2002","unstructured":"Li S et al (2002) Inverse relationship between six week postvaccination varicella antibody response to vaccine and likelihood of long term breakthrough infection. Pediatr Infect Dis J 21(4):337\u2013342","journal-title":"Pediatr Infect Dis J"},{"key":"245_CR84","doi-asserted-by":"crossref","unstructured":"Li S et al (2017) Metabolic phenotypes of response to vaccination in humans. Cell 169(5):862\u2013877 e17","DOI":"10.1016\/j.cell.2017.04.026"},{"issue":"3","key":"245_CR85","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.immuni.2006.06.019","volume":"25","author":"L Liu","year":"2006","unstructured":"Liu L et al (2006) Dynamic programing of CD8+ T cell trafficking after live viral immunization. Immunity 25(3):511\u2013520","journal-title":"Immunity"},{"issue":"34","key":"245_CR86","doi-asserted-by":"publisher","first-page":"902","DOI":"10.15585\/mmwr.mm6534a4","volume":"65","author":"AS Lopez","year":"2016","unstructured":"Lopez AS, Zhang J, Marin M (2016) Epidemiology of Varicella during the 2-dose Varicella vaccination program\u2014United States, 2005\u20132014. MMWR Morb Mortal Wkly Rep 65(34):902\u2013905","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"11","key":"245_CR87","doi-asserted-by":"publisher","first-page":"894","DOI":"10.4161\/hv.6.11.12852","volume":"6","author":"CR MacIntyre","year":"2010","unstructured":"MacIntyre CR et al (2010) Concomitant administration of zoster and pneumococcal vaccines in adults \u226560 years old. Hum Vaccin 6(11):894\u2013902","journal-title":"Hum Vaccin"},{"key":"245_CR88","doi-asserted-by":"crossref","unstructured":"Marin M et al (2016) Global Varicella Vaccine Effectiveness: A Meta-analysis. Pediatrics 137(3):e20153741","DOI":"10.1542\/peds.2015-3741"},{"key":"245_CR89","unstructured":"Marin M et al (2007) Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 56(RR-4):1\u201340"},{"issue":"10","key":"245_CR90","doi-asserted-by":"publisher","first-page":"5167","DOI":"10.4049\/jimmunol.164.10.5167","volume":"164","author":"Z Mikloska","year":"2000","unstructured":"Mikloska Z et al (2000) Monophosphoryl lipid A and QS21 increase CD8 T lymphocyte cytotoxicity to herpes simplex virus-2 infected cell proteins 4 and 27 through IFN-gamma and IL-12 production. J Immunol 164(10):5167\u20135176","journal-title":"J Immunol"},{"issue":"6","key":"245_CR91","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1093\/cid\/ciu918","volume":"60","author":"VA Morrison","year":"2015","unstructured":"Morrison VA et al (2015) Long-term persistence of zoster vaccine efficacy. Clin Infect Dis 60(6):900\u2013909","journal-title":"Clin Infect Dis"},{"issue":"2","key":"245_CR92","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/nri.2015.3","volume":"16","author":"SN Mueller","year":"2016","unstructured":"Mueller SN, Mackay LK (2016) Tissue-resident memory T cells: local specialists in immune defence. Nat Rev Immunol 16(2):79\u201389","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"245_CR93","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/infdis\/171.1.13","volume":"171","author":"S Nader","year":"1995","unstructured":"Nader S et al (1995) Age-related differences in cell-mediated immunity to varicella-zoster virus among children and adults immunized with live attenuated varicella vaccine. J Infect Dis 171(1):13\u201317","journal-title":"J Infect Dis"},{"key":"245_CR94","doi-asserted-by":"crossref","unstructured":"Ngai AL et al (1996) Safety and immunogenicity of one vs. two injections of Oka\/Merck varicella vaccine in healthy children. Pediatr Infect Dis J 15(1):49\u201354","DOI":"10.1097\/00006454-199601000-00011"},{"issue":"3","key":"245_CR95","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1128\/CVI.00818-13","volume":"21","author":"B Ogunjimi","year":"2014","unstructured":"Ogunjimi B et al (2014) Influence of frequent infectious exposures on general and varicella-zoster virus-specific immune responses in pediatricians. Clin Vaccine Immunol 21(3):417\u2013426","journal-title":"Clin Vaccine Immunol"},{"issue":"22","key":"245_CR96","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa051016","volume":"352","author":"MN Oxman","year":"2005","unstructured":"Oxman MN et al (2005) A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 352(22):2271\u20132284","journal-title":"N Engl J Med"},{"issue":"2\u20133","key":"245_CR97","first-page":"39","volume":"27","author":"T Ozaki","year":"1984","unstructured":"Ozaki T et al (1984) Clinical trial of the Oka strain of live attenuated varicella vaccine on healthy children. Biken J 27(2\u20133):39\u201342","journal-title":"Biken J"},{"issue":"5","key":"245_CR98","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1056\/NEJMoa1401177","volume":"371","author":"SY Pai","year":"2014","unstructured":"Pai SY et al (2014) Transplantation outcomes for severe combined immunodeficiency, 2000\u20132009. N Engl J Med 371(5):434\u2013446","journal-title":"N Engl J Med"},{"issue":"14","key":"245_CR99","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1016\/j.vaccine.2016.10.055","volume":"35","author":"J Parrino","year":"2017","unstructured":"Parrino J et al (2017) Safety and immunogenicity of inactivated varicella-zoster virus vaccine in adults with hematologic malignancies receiving treatment with anti-CD20 monoclonal antibodies. Vaccine 35(14):1764\u20131769","journal-title":"Vaccine"},{"issue":"3","key":"245_CR100","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S1473-3099(18)30716-3","volume":"19","author":"M Povey","year":"2019","unstructured":"Povey M et al (2019) Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: 10-year follow-up of a phase 3 multicentre, observer-blind, randomised, controlled trial. Lancet Infect Dis 19(3):287\u2013297","journal-title":"Lancet Infect Dis"},{"key":"245_CR101","doi-asserted-by":"crossref","unstructured":"Qi Q et al (2016) Diversification of the antigen-specific T cell receptor repertoire after varicella zoster vaccination. Sci Transl Med 8(332):332ra46","DOI":"10.1126\/scitranslmed.aaf1725"},{"issue":"9","key":"245_CR102","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1586\/erv.11.93","volume":"10","author":"M Quinlivan","year":"2011","unstructured":"Quinlivan M, Breuer J, Schmid DS (2011) Molecular studies of the Oka varicella vaccine. Expert Rev Vaccines 10(9):1321\u20131336","journal-title":"Expert Rev Vaccines"},{"issue":"5","key":"245_CR103","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1128\/JCM.06630-11","volume":"50","author":"ML Quinlivan","year":"2012","unstructured":"Quinlivan ML et al (2012) Novel genetic variation identified at fixed loci in ORF62 of the Oka varicella vaccine and in a case of vaccine-associated herpes zoster. J Clin Microbiol 50(5):1533\u20131538","journal-title":"J Clin Microbiol"},{"issue":"6","key":"245_CR104","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1172\/JCI132583","volume":"130","author":"P Roychoudhury","year":"2020","unstructured":"Roychoudhury P et al (2020) Tissue-resident T cell-derived cytokines eliminate herpes simplex virus-2-infected cells. J Clin Invest 130(6):2903\u20132919","journal-title":"J Clin Invest"},{"issue":"7","key":"245_CR105","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1093\/cid\/cir970","volume":"54","author":"KE Schmader","year":"2012","unstructured":"Schmader KE et al (2012) Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50\u201359 years. Clin Infect Dis Official Publ Infect Dis Soc Am 54(7):922\u2013928","journal-title":"Clin Infect Dis Official Publ Infect Dis Soc Am"},{"issue":"12","key":"245_CR106","doi-asserted-by":"publisher","first-page":"e00240","DOI":"10.1128\/JVI.00240-21","volume":"95","author":"DS Schmid","year":"2021","unstructured":"Schmid DS et al (2021) Comparative antibody responses to the live-attenuated and recombinant herpes zoster vaccines. J Virol 95(12):e00240-e321","journal-title":"J Virol"},{"issue":"8","key":"245_CR107","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1097\/INF.0b013e318170bb22","volume":"27","author":"V Schuster","year":"2008","unstructured":"Schuster V et al (2008) Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life. Pediatr Infect Dis J 27(8):724\u2013730","journal-title":"Pediatr Infect Dis J"},{"issue":"6","key":"245_CR108","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1080\/21645515.2018.1442162","volume":"14","author":"TF Schwarz","year":"2018","unstructured":"Schwarz TF et al (2018) Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults. Hum Vaccin Immunother 14(6):1370\u20131377","journal-title":"Hum Vaccin Immunother"},{"key":"245_CR109","doi-asserted-by":"publisher","first-page":"553","DOI":"10.3389\/fimmu.2015.00553","volume":"6","author":"JJ Sei","year":"2015","unstructured":"Sei JJ et al (2015) Effector and central memory poly-functional CD4(+) and CD8(+) T cells are boosted upon ZOSTAVAX((R)) vaccination. Front Immunol 6:553","journal-title":"Front Immunol"},{"issue":"1","key":"245_CR110","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/cei.13189","volume":"194","author":"JA Seidel","year":"2018","unstructured":"Seidel JA et al (2018) Skin resident memory CD8+ T cells are phenotypically and functionally distinct from circulating populations and lack immediate cytotoxic function. Clin Exp Immunol 194(1):79\u201392","journal-title":"Clin Exp Immunol"},{"issue":"6","key":"245_CR111","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1001\/jama.292.6.704","volume":"292","author":"JF Seward","year":"2004","unstructured":"Seward JF et al (2004) Contagiousness of varicella in vaccinated cases: a household contact study. JAMA 292(6):704\u2013708","journal-title":"JAMA"},{"issue":"4","key":"245_CR112","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/hiv.12311","volume":"17","author":"SD Shafran","year":"2016","unstructured":"Shafran SD (2016) Live attenuated herpes zoster vaccine for HIV-infected adults. HIV Med 17(4):305\u2013310","journal-title":"HIV Med"},{"issue":"3","key":"245_CR113","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1093\/infdis\/jiq052","volume":"203","author":"ED Shapiro","year":"2011","unstructured":"Shapiro ED et al (2011) Effectiveness of 2 doses of varicella vaccine in children. J Infect Dis 203(3):312\u2013315","journal-title":"J Infect Dis"},{"issue":"5","key":"245_CR114","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1093\/infdis\/165.5.852","volume":"165","author":"M Sharp","year":"1992","unstructured":"Sharp M et al (1992) Kinetics and viral protein specificity of the cytotoxic T lymphocyte response in healthy adults immunized with live attenuated varicella vaccine. J Infect Dis 165(5):852\u2013858","journal-title":"J Infect Dis"},{"issue":"6","key":"245_CR115","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1097\/00006454-200206000-00014","volume":"21","author":"HR Shinefield","year":"2002","unstructured":"Shinefield HR et al (2002) Vaccination with measles, mumps and rubella vaccine and varicella vaccine: safety, tolerability, immunogenicity, persistence of antibody and duration of protection against varicella in healthy children. Pediatr Infect Dis J 21(6):555\u2013561","journal-title":"Pediatr Infect Dis J"},{"issue":"7","key":"245_CR116","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1097\/INF.0b013e318060d33d","volume":"26","author":"JL Silber","year":"2007","unstructured":"Silber JL et al (2007) Immunogenicity of Oka\/Merck varicella vaccine in children vaccinated at 12\u201314 months of age versus 15\u201323 months of age. Pediatr Infect Dis J 26(7):572\u2013576","journal-title":"Pediatr Infect Dis J"},{"issue":"19","key":"245_CR117","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1182\/blood-2014-04-573048","volume":"124","author":"EA Stadtmauer","year":"2014","unstructured":"Stadtmauer EA et al (2014) A phase 1\/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients. Blood 124(19):2921\u20132929","journal-title":"Blood"},{"issue":"6","key":"245_CR118","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1002\/jmv.20838","volume":"79","author":"K Suzuki","year":"2007","unstructured":"Suzuki K et al (2007) Isolation of therapeutic human monoclonal antibodies for varicella-zoster virus and the effect of light chains on the neutralizing activity. J Med Virol 79(6):852\u2013862","journal-title":"J Med Virol"},{"issue":"3","key":"245_CR119","doi-asserted-by":"publisher","first-page":"667","DOI":"10.4161\/hv.27382","volume":"10","author":"S Tafuri","year":"2014","unstructured":"Tafuri S et al (2014) Determinants of varicella breakthrough: results of a 2012 case control study. Hum Vaccin Immunother 10(3):667\u2013670","journal-title":"Hum Vaccin Immunother"},{"issue":"2\u20133","key":"245_CR120","first-page":"31","volume":"27","author":"M Takahashi","year":"1984","unstructured":"Takahashi M (1984) Development and characterization of a live varicella vaccine (Oka strain). Biken J 27(2\u20133):31\u201336","journal-title":"Biken J"},{"issue":"1","key":"245_CR121","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/1096-9071(200009)62:1<46::AID-JMV8>3.0.CO;2-Y","volume":"62","author":"K Terada","year":"2000","unstructured":"Terada K et al (2000) Low induction of varicella-zoster virus-specific secretory IgA antibody after vaccination. J Med Virol 62(1):46\u201351","journal-title":"J Med Virol"},{"issue":"10","key":"245_CR122","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1089\/aid.2019.0053","volume":"35","author":"A Tovar Salazar","year":"2019","unstructured":"Tovar Salazar A et al (2019) Immune correlates of herpes zoster in people living with HIV on effective antiretroviral therapy. AIDS Res Hum Retroviruses 35(10):890\u2013895","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"20","key":"245_CR123","doi-asserted-by":"publisher","first-page":"3628","DOI":"10.1016\/j.vaccine.2011.03.018","volume":"29","author":"HF Tseng","year":"2011","unstructured":"Tseng HF et al (2011) Evaluation of the incidence of herpes zoster after concomitant administration of zoster vaccine and polysaccharide pneumococcal vaccine. Vaccine 29(20):3628\u20133632","journal-title":"Vaccine"},{"issue":"12","key":"245_CR124","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1093\/infdis\/jiw047","volume":"213","author":"HF Tseng","year":"2016","unstructured":"Tseng HF et al (2016) Declining effectiveness of herpes zoster vaccine in adults aged >\/=60 years. J Infect Dis 213(12):1872\u20131875","journal-title":"J Infect Dis"},{"issue":"Suppl 3","key":"245_CR125","doi-asserted-by":"publisher","first-page":"S330","DOI":"10.1093\/infdis\/174.Supplement_3.S330","volume":"174","author":"T Varis","year":"1996","unstructured":"Varis T, Vesikari T (1996) Efficacy of high-titer live attenuated varicella vaccine in healthy young children. J Infect Dis 174(Suppl 3):S330\u2013S334","journal-title":"J Infect Dis"},{"issue":"13","key":"245_CR126","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1056\/NEJM200103293441302","volume":"344","author":"M Vazquez","year":"2001","unstructured":"Vazquez M et al (2001) The effectiveness of the varicella vaccine in clinical practice. N Engl J Med 344(13):955\u2013960","journal-title":"N Engl J Med"},{"issue":"9","key":"245_CR127","doi-asserted-by":"publisher","first-page":"3496","DOI":"10.1073\/pnas.0610847104","volume":"104","author":"GM Verjans","year":"2007","unstructured":"Verjans GM et al (2007) Selective retention of herpes simplex virus-specific T cells in latently infected human trigeminal ganglia. Proc Natl Acad Sci U S A 104(9):3496\u20133501","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"245_CR128","first-page":"181","volume":"70","author":"P Vink","year":"2020","unstructured":"Vink P et al (2020) Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in chronically immunosuppressed adults following renal transplant: a phase 3 randomized clinical trial. Clin Infect Dis 70(2):181\u2013190","journal-title":"Clin Infect Dis"},{"key":"245_CR129","doi-asserted-by":"crossref","unstructured":"Voic H et al (2020) Identification and Characterization of CD4(+) T Cell Epitopes after Shingrix Vaccination. J Virol 94(24):e01641\u201320","DOI":"10.1128\/JVI.01641-20"},{"issue":"1","key":"245_CR130","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1086\/421277","volume":"190","author":"MT Vossen","year":"2004","unstructured":"Vossen MT et al (2004) Development of virus-specific CD4+ T cells on reexposure to Varicella-Zoster virus. J Infect Dis 190(1):72\u201382","journal-title":"J Infect Dis"},{"issue":"7","key":"245_CR131","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1038\/jid.2015.63","volume":"135","author":"M Vukmanovic-Stejic","year":"2015","unstructured":"Vukmanovic-Stejic M et al (2015) The characterization of varicella zoster virus-specific T cells in skin and blood during aging. J Invest Dermatol 135(7):1752\u20131762","journal-title":"J Invest Dermatol"},{"issue":"4","key":"245_CR132","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1093\/infdis\/162.4.794","volume":"162","author":"B Watson","year":"1990","unstructured":"Watson B et al (1990) Cell-mediated immune responses after immunization of healthy seronegative children with varicella vaccine: kinetics and specificity. J Infect Dis 162(4):794\u2013799","journal-title":"J Infect Dis"},{"issue":"1","key":"245_CR133","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1542\/peds.91.1.17","volume":"91","author":"BM Watson","year":"1993","unstructured":"Watson BM et al (1993) Modified chickenpox in children immunized with the Oka\/Merck varicella vaccine. Pediatrics 91(1):17\u201322","journal-title":"Pediatrics"},{"issue":"2","key":"245_CR134","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1093\/clinids\/20.2.316","volume":"20","author":"B Watson","year":"1995","unstructured":"Watson B et al (1995) Humoral and cell-mediated immune responses in healthy children after one or two doses of varicella vaccine. Clin Infect Dis 20(2):316\u2013319","journal-title":"Clin Infect Dis"},{"key":"245_CR136","doi-asserted-by":"crossref","unstructured":"Weibel RE et al (1984) Live attenuated varicella virus vaccine. Efficacy trial in healthy children. N Engl J Med 310(22):1409\u20131415","DOI":"10.1056\/NEJM198405313102201"},{"issue":"17","key":"245_CR135","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1001\/jama.1985.03360170075034","volume":"254","author":"RE Weibel","year":"1985","unstructured":"Weibel RE et al (1985) Live Oka\/Merck varicella vaccine in healthy children. Further clinical and laboratory assessment. JAMA 254(17):2435\u20132439","journal-title":"JAMA"},{"issue":"7","key":"245_CR137","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1086\/651199","volume":"201","author":"A Weinberg","year":"2010","unstructured":"Weinberg A et al (2010) Influence of age and nature of primary infection on varicella-zoster virus-specific cell-mediated immune responses. J Infect Dis 201(7):1024\u20131030","journal-title":"J Infect Dis"},{"issue":"5","key":"245_CR138","doi-asserted-by":"publisher","first-page":"2878","DOI":"10.1128\/JVI.06623-11","volume":"86","author":"A Weinberg","year":"2012","unstructured":"Weinberg A et al (2012) Immune correlates of herpes zoster in HIV-infected children and youth. J Virol 86(5):2878\u20132881","journal-title":"J Virol"},{"issue":"Suppl 1","key":"245_CR139","doi-asserted-by":"publisher","first-page":"S413","DOI":"10.1093\/ofid\/ofx163.1036","volume":"4","author":"A Weinberg","year":"2017","unstructured":"Weinberg A et al (2017) Immune senescence factors associated with the immunogenicity of a live attenuated zoster vaccine (ZV) in older adults. Open Forum Infect Dis 4(Suppl 1):S413\u2013S414","journal-title":"Open Forum Infect Dis"},{"key":"245_CR140","doi-asserted-by":"crossref","unstructured":"Weinberg A et al (2019) The effect of age on the immunogenicity of the live attenuated zoster vaccine is predicted by baseline regulatory T cells and varicella-zoster virus-specific T cell immunity. J Virol 93(15)","DOI":"10.1128\/JVI.00305-19"},{"issue":"37","key":"245_CR141","doi-asserted-by":"publisher","first-page":"5880","DOI":"10.1016\/j.vaccine.2020.05.006","volume":"38","author":"S Weinmann","year":"2020","unstructured":"Weinmann S et al (2020) Incidence of herpes zoster among varicella-vaccinated children, by number of vaccine doses and simultaneous administration of measles, mumps, and rubella vaccine. Vaccine 38(37):5880\u20135884","journal-title":"Vaccine"},{"issue":"5","key":"245_CR142","first-page":"604","volume":"87","author":"CJ White","year":"1991","unstructured":"White CJ et al (1991) Varicella vaccine (VARIVAX) in healthy children and adolescents: results from clinical trials, 1987\u20131989. Pediatrics 87(5):604\u2013610","journal-title":"Pediatrics"},{"issue":"1","key":"245_CR143","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/00006454-199201000-00006","volume":"11","author":"CJ White","year":"1992","unstructured":"White CJ et al (1992) Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response. Pediatr Infect Dis J 11(1):19\u201323","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"245_CR144","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/infdis\/165.1.119","volume":"165","author":"A Wilson","year":"1992","unstructured":"Wilson A et al (1992) Subclinical varicella-zoster virus viremia, herpes zoster, and T lymphocyte immunity to varicella-zoster viral antigens after bone marrow transplantation. J Infect Dis 165(1):119\u2013126","journal-title":"J Infect Dis"},{"issue":"10135","key":"245_CR145","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1016\/S0140-6736(18)30631-7","volume":"391","author":"DJ Winston","year":"2018","unstructured":"Winston DJ et al (2018) Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial. Lancet 391(10135):2116\u20132127","journal-title":"Lancet"},{"key":"245_CR146","doi-asserted-by":"crossref","unstructured":"Wu X et al (2018) CD8+ Resident Memory T Cells and Viral Infection. Front Immunol 9(2093)","DOI":"10.3389\/fimmu.2018.02093"},{"issue":"2\u20133","key":"245_CR147","first-page":"43","volume":"27","author":"H Yabuuchi","year":"1984","unstructured":"Yabuuchi H et al (1984) A live varicella vaccine in a pediatric community. Biken J 27(2\u20133):43\u201349","journal-title":"Biken J"},{"issue":"4","key":"245_CR148","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1093\/infdis\/147.4.737","volume":"147","author":"JA Zaia","year":"1983","unstructured":"Zaia JA et al (1983) Evaluation of varicella-zoster immune globulin: protection of immunosuppressed children after household exposure to varicella. J Infect Dis 147(4):737\u2013743","journal-title":"J Infect Dis"}],"container-title":["Current Topics in Microbiology and Immunology","Varicella-zoster Virus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/82_2021_245","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T14:48:53Z","timestamp":1680792533000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/82_2021_245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"ISBN":["9783031153044","9783031153051"],"references-count":148,"URL":"https:\/\/doi.org\/10.1007\/82_2021_245","relation":{},"ISSN":["0070-217X","2196-9965"],"issn-type":[{"value":"0070-217X","type":"print"},{"value":"2196-9965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"1 February 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}